AE
AEMD.US Aethlon Medical Inc
- Market cap
- USD 8.95M
- P/E
- -
- P/B
- 0.77x
- ROE
- -119.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AEMD.US undervalued?
Graham numberThe Graham number of Aethlon Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aethlon Medical Inc fundamental analysis
No fundamental analysis for Aethlon Medical Inc yet.
Aethlon Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aethlon Medical Inc
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
Full company profileAethlon Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aethlon Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 392K | 150K | 230K | 650K | 659K | 294K | 574K | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -3.09B | -2.49B | -2.85B | 650K | 659K | 294K | 574K | -359K | -340K | - | -594K |
| Operating Income | -6.10M | -4.83M | -6.00M | -5.93M | -7.89M | -10.4M | -11.9M | -12.6M | -9.34M | -7.29M | -6.32M |
| EBITDA | -6.97M | -5.30M | -5.97M | -5.90M | -7.85M | -10.3M | -11.8M | -11.8M | -13.0M | -6.81M | -5.60M |
| Net Income | -7.28M | -5.68M | -6.20M | -6.37M | -7.85M | -10.4M | -12.0M | -12.2M | -13.4M | -7.15M | -6.19M |
| EPS | -141 | -69 | -513 | -187 | -519 | -565 | -469 | -389 | -86 | -11 | -16 |
| Balance Sheet | |||||||||||
| Total Assets | 1.73M | 7.35M | 4.12M | 10.4M | 10.7M | 19.4M | 17.5M | 8.25M | 7.36M | 6.33M | 6.24M |
| Total Liabilities | 1.13M | 1.32M | 1.82M | 1.11M | 1.38M | 2.43M | 2.44M | 2.48M | 2.24M | 1.45M | 1.04M |
| Shareholders' Equity | 595K | 6.03M | 2.43M | 9.41M | 9.43M | 17.1M | 15.1M | 5.77M | 5.12M | 4.89M | 5.20M |
| Cash & Short-term Investments | 1.56M | 6.97M | 3.83M | 9.60M | 9.86M | 17.1M | 14.5M | 5.44M | 5.50M | 5.03M | 4.93M |
| Total Debt | 519K | 841K | 962K | 141K | 42.5K | 729K | 1.21M | 940K | 650K | 337K | 368K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.51M | -3.91M | -4.29M | -5.20M | -6.76M | -9.77M | -10.5M | -10.1M | -7.65M | -7.00M | -7.59M |
| Capital Expenditure | 16.4K | 24.8K | 152K | 152K | 59.9K | 349K | 943K | 251K | 2.00 | 3.70K | 36.6K |
| Free Cash Flow | -3.52M | -3.94M | -4.29M | -5.35M | -6.82M | -10.1M | -11.4M | -10.4M | -7.65M | -7.00M | -7.62M |
| Ratios | |||||||||||
| ROE | -1,222.0% | -94.2% | -255.5% | -67.7% | -83.2% | -60.8% | -79.9% | -211.7% | -261.3% | -146.4% | -119.1% |
| ROA | -421.5% | -77.3% | -150.3% | -61.4% | -73.6% | -53.6% | -68.7% | -148.0% | -181.9% | -112.9% | -99.3% |
| Net Profit Margin | -1,855.8% | -3,796.2% | -2,697.9% | -980.3% | -1,190.8% | -3,540.9% | -2,094.9% | - | - | - | - |
| Debt to Equity | 0.87x | 0.14x | 0.40x | 0.01x | 0.00x | 0.04x | 0.08x | 0.16x | 0.13x | 0.07x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aethlon Medical Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 40.9K | 1.20 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on Aug 4, 2026.
Who owns Aethlon Medical Inc
- Insiders 3.13%
- Institutions 8.47%
- Public & others 88.41%
- Shares outstanding 1.60M
- Free float 703K
Top funds holding AEMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 1.75K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 215.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding AEMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 72.7K | 2.05% | 0.00% | Jun 2026 |
| Shay Capital LLC | 31.1K | 0.87% | +119.99% | Jun 2026 |
| Ikarian Capital, LLC | 14.4K | 0.40% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 10.2K | 0.29% | -58.18% | Jun 2026 |
| Scientech Research LLC | 10.1K | 0.28% | 0.00% | Jun 2026 |
| UBS Group AG | 8.88K | 0.25% | +891.73% | Jun 2026 |
| Tower Research Capital LLC | 6.33K | 0.18% | +292.99% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.47K | 0.07% | +20.76% | Jun 2026 |
| Group One Trading, LLC | 14.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 10.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
Aethlon Medical Inc company profile
- Company name
- Aethlon Medical Inc
- Ticker
- AEMD.US
- Exchange
- USA Stocks
- Listed since
- Jan 2, 2001
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 9
- Fiscal year end
- March
- Address
- 11555 Sorrento Valley Road, San Diego, CA, United States, 92121
- Phone
- 619 941 0360
- Website
- aethlonmedical.com
About Aethlon Medical Inc
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
Aethlon Medical Inc management
3- Mr. James B. Frakes M.B.A.CEO, CFO, Chief Accounting Officer, Secretary & Director · born 1957
- Dr. Steven P. LaRosa M.D.Chief Medical Officer · born 1967
- Ms. Michele BombardiereVP & Controller